ArticleTranslational cancer research2025
Prognostic factor analysis and nomogram construction for elderly patients with stages III and IV epithelial ovarian cancer: a study based on the SEER database.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial ovarian cancer (EOC), one of the most fatal diseases affecting the elderly women. Advanced stages EOC (stage III and stage IV) presents significant challenges in prognosis and treatment due to factors such as poor treatment tolerance, comorbidities, and immune dysfunction. There is a lack of reliable prognostic tools for elderly EOC patients. This study aimed to develop two nomograms to predict overall survival (OS) and cancer-specific survival (CSS) in elderly patients with advanced-stage EOC using Surveillance, Epidemiology, and End Results (SEER) database, providing a tool for more personalized treatment decisions. Methods: Data about patients diagnosed with ovarian cancer at stages III and IV from 2010 to 2015 were extracted from the SEER database. Participants were randomly assigned to a training set and a validation set in a 7:3 ratio with OS and CSS as outcome events. Independent prognostic indicators determined in the multivariable analysis were employed in nomograms for predicting 1-, 3-, and 5-year OS and CSS for elderly EOC patients. The predictive performance and clinical utility were assessed using the concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: The majority of included participants were in stage III (71.38%), while 28.62% were in stage IV. In the OS training set, identified independent prognostic factors included age, race, marital status, tumor grade, T stage, American Joint Committee on Cancer (AJCC) stage, laterality, surgical method, chemotherapy, and cancer antigen 125 (CA-125). In the CSS training set, all these factors were retained except for the variable 'race'. The area under the ROC curve (AUC) for OS in the training set was 0.77 (0.75, 0.80) for 1-year, 0.68 (0.66, 0.70) for 3-year, and 0.66 (0.63, 0.68) for 5-year; in the validation set, the AUCs were 0.74 (0.70, 0.79), 0.69 (0.66, 0.72), and 0.70 (0.67, 0.73), respectively. For CSS in the training set, the AUCs were 0.77 (0.74, 0.79), 0.68 (0.66, 0.70), and 0.67 (0.64, 0.69) for 1, 3, and 5 years; in the validation set, the AUCs were 0.76 (0.71, 0.81), 0.66 (0.63, 0.70), and 0.67 (0.63, 0.70). These results indicate that the developed nomograms possess robust discriminative ability in predicting patients' OS and CSS. Conclusions: This study establishes clinically relevant nomograms for elderly patients with advanced ovarian cancer, demonstrating significant diagnostic value in predicting OS and CSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.